INTRODUCTION
Despite the growing availability of genomic diagnostic tests, many children with suspected genetic diseases remain undiagnosed until adulthood. 1 However, with the decreasing cost and increased availability of sequencing technologies, clinical exome sequencing (CES) is quickly becoming a leading modality in pediatric patients referred for clinical genetics evaluation. [2] [3] [4] Early results from centers that have piloted the use of CES in pediatric genetic clinics have been promising, with several groups showing up to a 50% diagnosis rate, 2-5 compared to non-CES-based genetic tests such as chromosomal microarray (CMA), which typically yields a diagnosis in only about 15-20% of patients. 6 In addition, detailed cost analyses are beginning to show that, when used in appropriate patients, CES is costeffective and is of greater diagnostic utility as compared to traditional chromosomal and microarray-based testing. 7, 8 However, while CES is quickly becoming a first test of choice for many genetic evaluations, it is most useful as a diagnostic tool when applied to the appropriate patient population. 9 A comprehensive clinical assessment of patients to place genetic test results into clinical context, such as performed in a general genetics clinic, remains essential, as diagnosis of trinucleotide repeat disorders, mitochondrial diseases, copy number variants, and imprinting disorders require molecular testing methods other than CES. 9 In an attempt to increase the diagnostic yield of CES, a number of approaches have been taken. Genetic information sharing platforms such as Matchmaker Exchange have been developed, 10 which emphasizes comprehensive patient phenotyping with the use of standardized vocabulary such as from the Human Phenotype Ontology database. 11 Many groups have also advocated for re-sequencing/re-analysis of patients with initially negative CES and a high suspicion of having a de novo variant based on expert clinical opinion. 12, 13 Furthermore, prior studies have shown a higher diagnostic yield of CES in patients with neurologic deficits, 2,14,15 multiple congenital anomalies, 16 and more severe symptomatology, 16, 17 further highlighting the importance of patient selection.
Here we describe the CES clinical pipeline instituted at the University of Michigan Pediatric Genetics Clinic. Specifically, we report on the first 523 cases evaluated in our clinic. We show that our local population is similar to those previously reported by other genetics clinics and laboratories. 2, 4 Moreover, through representative examples, we highlight how CES is changing pediatric clinical practice and furthering our understanding of the pathogenesis of many genetic diseases.
PATIENTS AND METHODS
The institutional review board of the University of Michigan approved this retrospective study. Patients who were referred to the Michigan Medicine Pediatric Genetics clinic for any reason and who underwent CES as part of their diagnostic workup were consecutively included in this study. Clinical evaluations of patients were performed in the comprehensive Pediatrics Genetics Clinic and included detailed evaluation of each individual and construction of a pedigree. Patients were clinically assessed by a physician (medical geneticist) who reviewed prior history and medical workup, performed a patient interview and physical exam, and ordered diagnostic testing. Patients selected for this cohort included all consecutive patients in whom CES was deemed clinically indicated by the assessing physician who presented for evaluation from October 1, 2012 through April 30, 2018.
Based on physician clinical evaluation and reviews of prior workup and diagnostic testing, a binary yes/no phenotype dataset was curated for all patients across all body systems and other developmental/neurodevelopmental categories. This phenotyping was performed by the Medical Geneticist and then entered into the phenotype database. This was done upon the patient's initial presentation to clinic before results from genetic testing had returned. The database was created in Excel format, and data were entered by genetic counselors after the patient had been evaluated in clinic. The database was subsequently updated with results of genetic testing when available. The clinical system phenotypes assessed for abnormalities were: ear/nose/throat, ophthalmologic, neuromuscular, cardiac, pulmonary, gastrointestinal (GI), renal, skeletal/connective tissue/vascular, skin/hair/teeth, endocrine, hematologic/immunologic, disorders of sexual development/ambiguous genitalia, metabolic/inborn errors of metabolism. A number of other non-body system categories were also assessed in a similar binary way: multiple congenital anomalies, dysmorphic features, cancer, developmental delay, autism spectrum disorder (ASD) or autism-like features, and any other behavioral phenotype not otherwise specified. In addition to these binary-curated features, all patients had a descriptive phenotypic summary, as well as demographic information (age, sex) and collation of any prior genetic/molecular testing including karyotype, CMA, or other single gene or panel-based molecular testing. Each clinical phenotype was assigned its corresponding Human Phenotype Ontology term (Supplementary Table 2 ).
All patients included in this study underwent CES as part of their clinical workup, based on physician clinical decision making. All patients were also required to have a separate genetic counseling appointment for pre-test counseling performed by a certified genetic counselor. CES was performed in a "send-out" manner, with 424 to GeneDx, 96 to Ambry, 2 to UCLA, and 1 to Fulgent. Clinical CES results were reported using the ACMG classification scheme; however, for research purposes, we modified reporting for analysis here by collapsing pathogenic and likely pathogenic variants into the same category (pathogenic variants). We have also included genes of uncertain significance (GUS)-i.e., genes whose biologic function is not known or disease association has not been established-as these may be informative for future gene discovery research.
Clinical phenotype data were analyzed by comparing summative analysis of the binary phenotypes. Analysis of variance was used to compare differences between groups, with P value < 0.05 considered significant.
RESULTS
Data collection for this study began October 1, 2012 and ended April 30, 2018, at which time 562 consecutive patients had been clinically evaluated and had CES testing. Patients with incomplete clinical phenotyping or CES data not yet returned were excluded, resulting in a total of 523 patients included in this analysis. One-hundred and fifty-seven out of the 523 patients (30%) had a pathogenic or likely pathogenic variant identified that established a genetic diagnosis (Table 1 , Supplementary  Table 1 ), which is in line with prior CES cohorts. 2, 4, 5 Interestingly, the remaining 365 patients did not have a pathogenic or likely pathogenic variant identified that could clearly establish a clinical genetic diagnosis; however, 243/523 (67%) of patients had at least 1 variant of uncertain significance (VUS) or 1 GUS. Only 120/523 (23%) of patients who were referred for evaluation had no variants reported. There were no major discrepancies observed between the CES laboratory report and our clinical interpretation of the data in the context of the patient's clinical features.
In our clinical phenotype analysis of these patients, we discovered a significant difference between the number of body systems affected and the likelihood of having a pathogenic variant by CES (Table 2) . Among patients with a pathogenic variant identified, 128/157 (81%) had neuromuscular dysfunction and 131/157 (83%) had developmental delay, consistent with the nervous system being the most common body system affected. Thirty-one out of 157 (20%) of patients with pathogenic variants had a clinical diagnosis of ASD. The next most common systems affected were ophthalmologic (76/157, 48%), GI (63/157, 40%), and skeletal/connective tissue/vascular (63/157, 40%). Forty-two percent of patients (67/157) had multiple congenital anomalies. The frequencies of individual systems affected were not significantly different between patients with pathogenic variants and those with one or more VUS or GUS. Surprisingly, only 26/157 (16%) of patients with an identifiable pathogenic variant had dysmorphic features on clinical exam.
Medical genetics clinical phenotyping in correlation with CES results shows that patients with more body system abnormalities on clinical exam more frequently have an identifiable pathogenic mutation and that neurologic dysfunction and/or neurodevelopmental abnormalities are the clinical phenotypes most commonly found to have a pathogenic variant. Placement of these results in CES allows for simultaneous consideration of multiple possible diagnoses An 8-month-old boy (ID #79) was referred for microcephaly and hypotonia. The child also had gastroesophageal reflux as well as myringotomy tube placement for chronic otitis media. An echocardiogram showed thickened aortic valve leaflets. Brain magnetic resonance imaging showed no structural abnormalities. Physical exam was notable for weight at the 9th percentile, length at the 5th percentile, and head circumference less than the 3rd percentile (and 50th percentile for a 4-month-old). A bifid lower incisor was noted as well as highly arched palate, anteriorly placed anus, and truncal hypotonia. Prior to referral to our clinic, karyotype, CMA, and Fragile X testing were all negative. Differential diagnoses included a primary microcephaly disorder (ASPM and 18 additional genes), Kabuki syndrome (KMT2D, KDM6A), Smith-Lemli-Opitz syndrome (DHCR7), and Dubowitz syndrome (molecular basis not yet known). In lieu of single-gene testing, CES was sent and identified a heterozygous de novo pathogenic variant in KMT2D, c.8856delC (p.Lys2953Argfs*51). This confirmed a diagnosis of Kabuki syndrome (OMIM 147920). In this case, CES allowed all differential diagnoses to be considered simultaneously, allowing for more rapid establishment of the correct diagnosis and appropriate clinical guidelines in this patient. This diagnosis was not previously considered for this patient; however, the clinical phenotype is consistent with those rare males with pathogenic MECP2 variants. 20 The patient has since developed medically refractory seizures. In this case, CES allowed us to make a diagnosis that otherwise was not being considered yet in retrospect is consistent with rarely described cases.
CES promotes recognition of rare presentations of known diseases

DISCUSSION
In this manuscript, we present data from 523 patients evaluated at the University of Michigan Pediatric Genetics clinic who underwent CES and systematic clinical phenotyping. We identified pathogenic or likely pathogenic variants in 30% of patients, similar rates to those previously reported. 2, 4, 5 Interestingly, 67% of patients without an identified pathogenic or likely pathogenic variant had at least one VUS or GUS, suggesting that our diagnostic rate will increase over time with variant reclassification and reanalysis. Also similar to prior reports, we found that a higher percentage of patients with a pathogenic or likely pathogenic variant had developmental delay and/or multiple congenital anomalies as compared to patients without any identified pathogenic or likely pathogenic variant, 2, 4, 16 suggesting that these patients may benefit the most from evaluation by a clinical geneticist and CES. Interestingly, among individuals with VUS or GUS, there were similar percentages of patients with developmental delay and multiple congenital anomalies, highlighting the importance of re-evaluation over time.
In our patient population, 120/523 (23%) patients referred had no variants reported. Surprisingly, 33% of those had ASD and 34% had behavioral abnormalities, whereas ASD was present in only 20% of patients with a pathogenic/likely pathogenic variant and behavioral abnormalities in 27% of cases with a pathogenic/likely pathogenic variant. This discrepancy suggests that other mechanisms such as epigenetic factors may be driving these neurobehavioral phenotypes in our patient population. Re-analysis of exome data in this population will likely increase diagnostic yield. While whole-genome sequencing (WGS) may help resolve some of these negative results, the diagnostic utility of WGS does not currently exceed CES, suggesting that genomic analysis at levels other than DNA variants may be clinically helpful, especially in targeted phenotypic groups such as these. 7 The increased availability and decreasing cost of advanced sequencing technologies have led to CES becoming an invaluable diagnostic tool for patients referred for general genetics evaluations. In particular, our cohort highlights three ways in which CES has influenced the clinical trajectory of our patients, by allowing for (a) simultaneous consideration of multiple diagnoses, (b) recognition of rare presentations of known disorders, and (c) diagnosis of very rare or newly defined disorders. Identification of new disease genes is also possible through further investigation of reported VUS and GUS. Widespread use of CES promises to increase the number of pediatric patients with a genetic diagnosis. Our results add to the growing body of literature showing that appropriate patient selection is essential to ensure maximal diagnostic utility of advanced sequencing techniques and help guide the general pediatrics community as to the types of patients who may benefit from CES.
Comprehensive clinical phenotyping remains of critical importance when working up patients for possible genetic disorders. As demonstrated here, CES and phenotyping is beneficial not just for the individual patient's diagnosis. In aggregate, this information can be used to help guide higher-level decisions about CES. As our results show, for instance, patients presenting with a neurodevelopmental phenotype or multiple system anomalies have a higher pre-test probability of having a pathogenic variant than those with fewer organ systems involved.
This study has a number of limitations. As with many clinical exome studies, our sample size is relatively small and limited to those patients being part of routine clinical evaluations. In addition, our clinical phenotyping pipeline employed several different clinical providers to perform assessments, which has the potential to increase variability in phenotyping. Also, while >80% of CES testing was performed at one laboratory (GeneDx), there were a number of other laboratories/companies used (Ambry, UCLA, Fulgent).
Establishment of a comprehensive clinical genotype-phenotype dataset as described here will help provide a basis for many future studies. For instance, further evaluation of patients with pathogenic or likely pathogenic variants is useful for determining how frequently genetic diagnoses change medical or surgical management, assisting with cost-benefit analyses for CES. Incorporation of other types of genomic data that are not currently used or very new in clinical testing, such as metabolomics and epigenomics, could also provide for new clinical correlations. Further, basic science investigations into the biologic roles of the identified VUS and GUS may also lead to discovery of new causative variants.
In conclusion, we present clinical phenotyping data coupled with CES information on 523 pediatric patients referred to a pediatric genetics clinic at the University of Michigan. Our results support prior studies showing that about one-third of such cases currently receive a molecular diagnosis via an identified pathogenic or likely pathogenic variant. Furthermore, our phenotype analysis suggests that patients with multiple congenital abnormalities are most likely to have an identified pathogenic or likely pathogenic variant and that neurologic and neurodevelopmental system abnormalities are the most common in patients with a pathogenic or likely pathogenic variant on CES. Three representative case studies place into perspective for the general pediatrics community how CES is rapidly changing clinical care.
